Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?
Publication
, Journal Article
Gattis, WA; Galanos, A; O'Connor, CM
Published in: Am Heart J
March 2001
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
March 2001
Volume
141
Issue
3
Start / End Page
331 / 333
Location
United States
Related Subject Headings
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- Angiotensin-Converting Enzyme Inhibitors
- Aged
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gattis, W. A., Galanos, A., & O’Connor, C. M. (2001). Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal? Am Heart J, 141(3), 331–333. https://doi.org/10.1067/mhj.2001.113228
Gattis, W. A., A. Galanos, and C. M. O’Connor. “Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?” Am Heart J 141, no. 3 (March 2001): 331–33. https://doi.org/10.1067/mhj.2001.113228.
Gattis WA, Galanos A, O’Connor CM. Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal? Am Heart J. 2001 Mar;141(3):331–3.
Gattis, W. A., et al. “Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?” Am Heart J, vol. 141, no. 3, Mar. 2001, pp. 331–33. Pubmed, doi:10.1067/mhj.2001.113228.
Gattis WA, Galanos A, O’Connor CM. Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal? Am Heart J. 2001 Mar;141(3):331–333.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
March 2001
Volume
141
Issue
3
Start / End Page
331 / 333
Location
United States
Related Subject Headings
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- Angiotensin-Converting Enzyme Inhibitors
- Aged
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology